Stay updated with breaking news from Your Own Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RenBio Announces the Award of Two Grants to Support Continued Development of Its Novel DNA Therapeutics MYO Technology™ Platform for Infectious Disease Applications - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- RenBio, a privately-held, preclinical biotechnology company leveraging its novel, proprietary MYO (Make Your Own) Technology™ platform to...
These monthly mailed boxes can help children and parents through the long days when school and daycare aren't available, from books and crafts to science projects and personal stylists.
<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.icemortgagetechnology.com%2F&esheet=52510456&newsitemid=20211018005400&lan=en-US&anchor=ICE+Mortgage+Technology&index=1&md5=53cb65b977f558e4d56eb6e09546e8cb" rel="nofollow" shape="rect">ICE Mortgage Technology</a><span> </span><sup>TM</sup><span>, part of Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, t...
Share this article NEW YORK, May 20, 2021 /PRNewswire/ -- RenBio, a privately-held, preclinical biotechnology company developing novel, best-in-class antiviral antibody therapeutics and a next-generation antibody delivery platform, today announced that it has completed a $24 million Series A financing, led by Taiwan-based Ruentex Group. The company has also signed a license agreement with Columbia University, giving RenBio the exclusive worldwide development and commercialization rights to a novel bispecific antibody (RB-100) for COVID-19 that was developed in the lab of David D. Ho, M.D. o...